Santhera Pharmaceuticals AG Eyes Approval of Lead Drug, Catena in First Half of 2011

Published: Jun 16, 2010

Reuters -- Swiss Santhera is aiming to seek approval for lead drug Catena to treat a rare eye disease in the first half of 2011 after a trial showed it improved sight, boosting the biotech group's prospects.

Back to news